CN109152735B - 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法 - Google Patents

包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法 Download PDF

Info

Publication number
CN109152735B
CN109152735B CN201780026989.5A CN201780026989A CN109152735B CN 109152735 B CN109152735 B CN 109152735B CN 201780026989 A CN201780026989 A CN 201780026989A CN 109152735 B CN109152735 B CN 109152735B
Authority
CN
China
Prior art keywords
inflammatory
lipid
roflumide
lipid nanoparticle
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780026989.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109152735A (zh
Inventor
L.林福斯
T.凯尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN109152735A publication Critical patent/CN109152735A/zh
Application granted granted Critical
Publication of CN109152735B publication Critical patent/CN109152735B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780026989.5A 2016-05-09 2017-05-08 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法 Active CN109152735B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662333574P 2016-05-09 2016-05-09
US62/333574 2016-05-09
US201662359429P 2016-07-07 2016-07-07
US62/359429 2016-07-07
US201762449623P 2017-01-24 2017-01-24
US62/449623 2017-01-24
PCT/EP2017/060891 WO2017194454A1 (en) 2016-05-09 2017-05-08 Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof

Publications (2)

Publication Number Publication Date
CN109152735A CN109152735A (zh) 2019-01-04
CN109152735B true CN109152735B (zh) 2022-03-11

Family

ID=58671696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780026989.5A Active CN109152735B (zh) 2016-05-09 2017-05-08 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法

Country Status (6)

Country Link
US (2) US11458106B2 (https=)
EP (1) EP3454835B1 (https=)
JP (2) JP7066632B2 (https=)
CN (1) CN109152735B (https=)
ES (1) ES2871537T3 (https=)
WO (1) WO2017194454A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
LT3313829T (lt) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3454835B1 (en) 2016-05-09 2021-03-31 Astrazeneca AB Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
ES3063077T3 (en) * 2016-10-26 2026-04-15 Acuitas Therapeutics Inc Lipid nanoparticle formulations
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3668834B1 (en) 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
JP7543259B2 (ja) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
MY202837A (en) 2019-01-11 2024-05-24 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active agents
CN114173826A (zh) * 2019-05-08 2022-03-11 阿斯利康(瑞典)有限公司 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
KR20230002300A (ko) * 2020-01-21 2023-01-05 이더알엔에이 이뮤노테라피스 엔브이 지질 나노입자
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2023286059A1 (en) 2021-07-13 2023-01-19 Technion Research & Development Foundation Limited Compositions and methods for treating a medical condition
EP4427740A4 (en) * 2021-11-05 2025-10-22 G2Gbio Inc PHARMACEUTICAL KIT FOR PARENTERAL CO-ADMINISTRATION
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023148303A1 (de) * 2022-02-02 2023-08-10 Mslsolutions Gmbh Verfahren zur medikament- und impfstoffherstellung
CN114617980A (zh) * 2022-03-09 2022-06-14 广州国家实验室 可电离脂质纳米颗粒及其应用
US20240226133A1 (en) * 2023-01-09 2024-07-11 Claudia Chimisso Dos Santos Microrna-based particle for the treatment of dysregulated immune response
WO2025215636A1 (en) 2024-04-08 2025-10-16 Yeda Research And Development Co. Ltd. Anti-defense system polypeptides and uses thereof
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1171047A (zh) * 1994-12-22 1998-01-21 阿斯特拉公司 用于吸入法的原脂质体粉末
WO2006031471A2 (en) * 2004-09-01 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Liposomal vectors
CN104873464A (zh) * 2009-06-10 2015-09-02 阿尔尼拉姆医药品有限公司 改进的脂质制剂
CN105283175A (zh) * 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101708338B (zh) 2008-12-26 2014-06-04 中国人民解放军军事医学科学院放射与辐射医学研究所 含甾体结构的前药及其高度分散制剂
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012127037A2 (en) * 2011-03-24 2012-09-27 Leo Pharma A/S A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CN104114572A (zh) * 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
EP3454835B1 (en) 2016-05-09 2021-03-31 Astrazeneca AB Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1171047A (zh) * 1994-12-22 1998-01-21 阿斯特拉公司 用于吸入法的原脂质体粉末
WO2006031471A2 (en) * 2004-09-01 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Liposomal vectors
CN104873464A (zh) * 2009-06-10 2015-09-02 阿尔尼拉姆医药品有限公司 改进的脂质制剂
CN105283175A (zh) * 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
CN105338979A (zh) * 2013-05-03 2016-02-17 西莱克塔生物科技公司 用于增强cd4+调节性t细胞的方法和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis";Ahlstrom-Emanuelsson et al.;《CLINICAL AND EXPERIMENTAL ALLERGY》;20040531;第34卷(第5期);全文 *

Also Published As

Publication number Publication date
CN109152735A (zh) 2019-01-04
JP2022058438A (ja) 2022-04-12
WO2017194454A1 (en) 2017-11-16
JP2019514979A (ja) 2019-06-06
JP7066632B2 (ja) 2022-05-13
EP3454835A1 (en) 2019-03-20
EP3454835B1 (en) 2021-03-31
US20170367988A1 (en) 2017-12-28
US20220370370A1 (en) 2022-11-24
ES2871537T3 (es) 2021-10-29
US11458106B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
CN109152735B (zh) 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
Ferrer et al. Structure-dependent biodistribution of liposomal spherical nucleic acids
Pham Nanotherapeutic approaches for the treatment of rheumatoid arthritis
Yuan et al. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity
EP2919760B1 (en) Liposomes with an anchored blood brain barrier recognition peptide for an improved delivery of a drug into the brain
JP4885715B2 (ja) イリノテカン製剤
JP2002508765A (ja) リポソーム被包ポリヌクレオチド組成物および方法
CN112543629A (zh) 外泌体胞外囊泡及其使用方法
WO2008052766A2 (en) Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
Wang et al. Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration
Qin et al. Nanotechnology-based drug delivery systems for treating acute kidney injury
JP2023513302A (ja) 治療的に活性な作用物質を内皮へと送達するための脂質組成物およびその使用
Ji et al. Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a “nanoguard” for synergistic treatment of synucleinopathies
Lim et al. Development and application of novel peptide-formulated nanoparticles for treatment of atopic dermatitis
EP2422776A1 (en) Polyarginine nanocapsules
Marcato Pharmacokinetics and pharmacodynamics of nanomaterials
WO2022115604A2 (en) Long-acting and long-circulating delivery vehicles
KR101916941B1 (ko) 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법
Song et al. Microenvironments‐targeted nanomaterials for atherosclerosis therapy
CN119405823B (zh) 一种基于g四链体rna的蛋白降解靶向嵌合体及其制备方法与应用
US20040077888A1 (en) Polyamine-mediated transfection
CN114642734B (zh) 药物及siRNA共递送纳米复合物及其制备方法与应用
CN118340747A (zh) 一种脂质纳米颗粒及其制备方法和应用
CN115487314B (zh) 一种bis-5HT-Glu-NH2修饰的重楼皂苷II纳米胶束及其制备方法与应用
Khorrami et al. Conjugation of Gold Nanoparticles to the Anti‐IL17A Aptamer Improves Anti‐Inflammatory Effects of the Aptamer in the Experimental Imiquimod‐Induced Psoriasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant